HARP News and Press, Harpoon Therapeutics Inc. From 01/08/24

2024-01-08 12:31:47 ET More on Merck Merck's Soaring Stock: Examining The Euphoria Amidst Potential Pitfalls Merck: Smart Value For Potentially Strong Total Returns Merck to buy Harpoon in $680M all-cash deal (update) For further details see: Merck on tra...

2024-01-08 08:53:00 ET U.S. stock index futures on Monday pointed to a mixed open for Wall Street, as the first full trading week of the new year begins. The benchmark S&P 500 ( SP500 ) last week was unable to extend its blistering year-end 2023 rally. Here are some stocks to wa...

Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Harpoon Therapeutics...

2024-01-08 06:51:56 ET Summary Boeing and Spirit AeroSystems stocks drop after mid-air blowout incident involving a Boeing plane model. Merck is in talks to acquire Harpoon Therapeutics for around $700 million. Audacy files for bankruptcy as ad sales decline, plans to restruct...

2024-01-08 05:33:37 ET Related stock stories: Boeing: A New Explosive MAX And Stock Crisis? Boeing: The Real Cash Flow Growth Surprise Boeing: $10 Billion FCF Target Appears Realistic By FY25/26, Buy Shares of Boeing and Spirit AeroSystems plunge after mid-ai...

2024-01-08 02:39:13 ET Merck ( NYSE: MRK ) is reportedly in advanced talks to buy immuno-oncology company Harpoon Therapeutics ( NASDAQ: HARP ) for around $700M. Citing people familiar with the matter, Bloomberg News reported on Sunday that Merck ( MRK ) is discu...

2023-12-30 09:25:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

SOUTH SAN FRANCISCO, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced abstract acceptance and an upcoming rapid oral presentation of updated interim monotherapy data f...

• HPN217 was well tolerated and demonstrated robust and durable clinical activity at doses ranging from 2.15 to 24 mg in heavily pre-treated patients, including patients with prior exposure to BCMA-targeted therapy • At the 12 mg dose, cohorts demonstrated favorable acti...

2023-12-08 16:30:47 ET More on Harpoon Therapeutics Harpoon: HPN328 Data In 1st Half Of 2024 Makes This A Must Watch Biggest stock movers today: Chevron, EngageSmart, Crypto-focused stocks and more For further details see: Harpoon Therapeutics files to sell 25.75...